An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors
- First Posted Date
- 2013-01-23
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT01773421
- Locations
- 🇬🇧
The Christie Hospital, Manchester, United Kingdom
🇬🇧Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧University College London Hospital, London, United Kingdom
A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 856
- Registration Number
- NCT01767311
- Locations
- 🇬🇧
Facility #1, Swindon, United Kingdom
🇬🇧Facility #2, London, United Kingdom
🇰🇷Facility #4, Seoul, Korea, Republic of
A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal
- First Posted Date
- 2013-01-03
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT01759394
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2013-05-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01716897
- Locations
- 🇺🇸
California Clinical Trials/Parexel, Glendale, California, United States
2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly Subjects
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2013-10-11
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01673451
- Locations
- 🇺🇸
Parexel, California Clinical Trials, Culver City, California, United States
Open-Label Study of Bioavailability of E2006 Tablet Versus Capsule Formulations
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2013-05-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01673880
- Locations
- 🇺🇸
PPD Development, LLC, Austin, Texas, United States
Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 185
- Registration Number
- NCT01634360
Evaluation of the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic Drug
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-06-28
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT01630057
- Locations
- 🇮🇹
AO Universitaria Consorziale Policlinico di Bari, Bari, Italy
🇮🇹AO Universitaria Policlinico Paolo Giaccone dell'Universit? degli Studi di Palermo, Palermo, Italy
🇮🇹Irccs "E. Medea", Bosisio Parini, Italy
Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2016-07-28
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT01605162
Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
- First Posted Date
- 2012-05-17
- Last Posted Date
- 2016-12-30
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT01600859
© Copyright 2024. All Rights Reserved by MedPath